Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atopic dermatitis
Biotech
AbbVie ends development of IL-1 asset in ulcerative colitis
AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis after a phase 2 study revealed insufficient efficacy results.
Gabrielle Masson
Jul 31, 2025 12:32pm
Apogee claims IL-13 antibody sets new eczema treatment standard
Jul 7, 2025 8:29am
Nektar stock doubles as phase 2b eczema trial hits endpoints
Jun 24, 2025 9:20am
Leo's eczema prospect hits primary endpoint in phase 2b
May 9, 2025 7:30am
Amgen ignites Rocket program with wins in phase 3 eczema trials
Mar 10, 2025 5:48am
Q32 Bio sticks with bempikibart but lets go of staff
Feb 11, 2025 4:47am
